Clinical Study to Determine Safety and Efficacy of FPlus for Wrinkle Treatment

NCT01559233 | Completed

• 1 other identifier: FP1
• Study Type: interventional
• Target: 69
• Locations: 1 country
• Sites: 1

Brief Summary

Patient demand for non-surgical, non-invasive, and no-downtime wrinkle and rhytides treatment procedures has grown dramatically over the past decade as new treatments and technologies have been introduced. This study was performed in order to evaluate the efficacy and safety of the Invasix FPlus System, an innovative noninvasive system intended for wrinkles and rhytides treatment. Subjects were treated for face wrinkles and rhytides reduction and followed for 3 months after last treatment. In order to evaluate treatment efficacy, pre and post treatment photos were introduced to three uninvolved physicians for blinded evaluation.

Conditions

Facial Wrinkles and Rhytides Reduction

Outcome Measures

Primary Outcomes (1)

• Lack of adverse events during treatments with the FPlus device and 3 months following last treatment.

  4.5 months

Secondary Outcomes (1)

• Facial wrinkle reduction rate following 6 treatments with the FPlus device, as agreed 3 blinded dermatologists, based on Fitzpatrick wrinkle and elastosis scale.

  4.5 months

Study Arms (1)

FPlus

EXPERIMENTAL

Device: FPlus RF device for wrinkles and rhytide reduction

Interventions

FPlus RF device for wrinkles and rhytide reduction DEVICE

Six RF weekly treatments for face wrinkles and rhytides reduction using the FPlus device.

Also known as: RF treatment

FPlus

Eligibility Criteria

• Age: 21 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects with mild to moderate facial wrinkles and rhytides .
• Males and females 21 - 65 years of age.
• Willingness to follow the treatment schedule, and have photographs taken.

You may not qualify if:

• Pacemaker or internal defibrillator, or other implanted metallic or electronic device.
• Permanent implant in the treated area such as metal plates and screws or silicon, unless deep enough in the periosteal plane.
• Avoid treatment if intra-dermal or superficial sub-dermal areas have been injected with Botox/HA/collagen/fat injections or other augmentation methods with bio-material during last 6 months.
• Current or history of skin cancer, or any other type of cancer, or pre-malignant moles.
• Severe concurrent conditions, such as cardiac disorders.
• Pregnancy or nursing.
• Impaired immune system due to immunosuppressive diseases such as AIDS and HIV, or use of immunosuppressive medications.
• Patients with history of diseases stimulated by heat, such as recurrent Herpes Simplex in the treatment area, may be treated only following a prophylactic regime.
• Poorly controlled endocrine disorders, such as diabetes.
• Any active skin condition in the treatment area, such as sores, psoriasis, eczema, and rash.
• History of skin disorders, keloids, abnormal wound healing, as well as very dry and fragile skin.
• History of bleeding coagulopathies, or use of anticoagulants in the last 10 days.
• Any facial surgery performed within 12 months prior to treatment.
• Facial dermabrasion, facial resurfacing, or deep chemical peeling within the last 3 months.
• Having received treatment with light, laser, RF, or other devices in the treated area within 6 months.

Sponsors & Collaborators

• Invasix: lead

Study Sites (1)

AestheticPlastic Surgery Practice, SpaMedica

Toronto, ON M5R 3N8, Canada

Location

Study Officials

• Robert Stephen Mulholland, Dr.

  Invasix

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 17, 2012
• First Posted: March 21, 2012
• Study Start: February 1, 2011
• Primary Completion: February 1, 2012
• Study Completion: March 1, 2012
• Last Updated: March 21, 2012

Record last verified: 2012-03

Locations

CA (1)